Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 shareholder update, detailing plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. This candidate targets EGFR-mutated lung cancer and other cancers, complementing Kairos’ existing portfolio, which includes ENV-105, KROS-201, KROS-102, and ENV-205. The announcement underscores the company’s strategic focus on addressing drug resistance and immune suppression in cancer.
The company expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations. Notably, Kairos has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs. This funding provides a financial runway without diluting existing shareholders, a significant advantage for a development-stage biotech.
Kairos Pharma’s lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. The company’s approach aims to reverse drug resistance and restore effectiveness of standard therapies across multiple cancer types, addressing significant unmet medical needs. The addition of CL-741, a c-MET inhibitor, could provide a complementary mechanism to target EGFR-mutated lung cancers, a patient population with high unmet need.
The mid-year update highlights Kairos’ commitment to advancing its pipeline through strategic acquisitions and clinical development. The company’s ability to secure non-dilutive funding and progress multiple programs simultaneously positions it to potentially deliver value to patients and shareholders. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The full press release is available at https://ibn.fm/WuBOf.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s pipeline, including KROS-201, KROS-102, and ENV-205, targets various cancer pathways. The proposed acquisition of CL-741 represents a significant expansion into targeted therapies for lung cancer, a leading cause of cancer deaths worldwide. The company’s upcoming milestones, including data presentations and trial initiations, will be closely watched by investors and the oncology community. For more updates, visit the company’s newsroom at https://ibn.fm/KAPA.
